Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilars In US Drug Pricing Debate: Second Chance – Or Maybe Last Chance

Sep 02 2019

• By Michael McCaughan

Capitol Building, Washington DC

Related Content

USP Rivalry With US FDA Over Compendial Standards Provision Busts Into Open Legislative Fight

Jun 11 2019

Patent Thicketing Provision Cut From Bill Passed By US Senate Judiciary Committee

Jun 28 2019

Who Is The Best Minor League Player In The Drug Pricing Debate?

Jul 25 2019

Point-Of-Sale Rebates May Be Added To US Senate Finance Drug Pricing Bill

Jul 26 2019

Related Companies

AbbVie Inc.

Additional Topics

United States Biosimilars Legislation Pricing Debate Policy BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window